Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -19.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-9.8%)
  • Dividend yield for the last twelve months 2.9%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 73.5% higher than minimum and 5.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (48.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+2.7%)229.89
year average price 201.86  


year start price 178.01 2024-12-27

min close price 169.20 2025-01-22

max close price 244.38 2025-10-01

current price 229.89 2025-12-26
Common stocks: 1 768 480 508

Dividend Yield:  2.9%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 48.0x
EV / EBITDA annualized: 56.0x
Last revenue growth (y/y):  +9.1%
Last growth of EBITDA (y/y):  -47.9%
Historical revenue growth:  +1.2%
Historical growth of EBITDA:  -20.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 406 556
Net Debt ($m): 63 115
EV (Enterprise Value): 469 671
EBITDA LTM ($m): 9 787
EV / LTM EBITDA: 48.0x
Price to Book: -153.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-26zacks.com

The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio

2025-12-23zacks.com

5 Big Drug Stocks That May Continue to Outperform in 2026

2025-12-22fool.com

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

2025-12-16zacks.com

How AbbVie's Pipeline Is Lining Up Key Product Launches

2025-12-13fool.com

My Top 3 Healthcare Stocks to Buy in 2026

2025-12-13247wallst.com

5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine

2025-12-12zacks.com

AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock

2025-12-12marketbeat.com

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

2025-12-12fool.com

The Smartest Dividend Stocks to Buy With $5,000 Right Now

2025-12-11zacks.com

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data